Nautilus Biotechnology

Nautilus Biotechnology appoints Ken Suzuki as Chief Marketing Officer, leveraging his 25 years of leadership at Agilent Technologies, including the Mass Spectrometry division, to advance their single-molecule protein analysis platform.

Nautilus Biotechnology appoints Martin Huber, Ph.D., as VP of Biochemistry and Flow Cell Development, expanding its R&D senior leadership team.

Nautilus Biotechnology appoints Kentaro (Ken) Suzuki as Chief Marketing Officer. Suzuki, with 25 years at Agilent Technologies, most recently as VP and GM of Mass Spectrometry, brings extensive experience in life sciences and technology. He holds an M.B.A. from UC Berkeley and a B.S. in Biological Engineering from Cornell. Based in Nautilus' SF Bay Area R&D headquarters.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of bots. Account usually reactivates within 24 hours; contact support if still disabled.

Insiders hold 32% of Nautilus Biotechnology shares, benefiting most from a 11% stock rise. Institutions own a respectable stake, and top shareholders include Parag Mallick (16%) and Sujal Patel (14%). The public holds 13%, and private equity firms control 30%. Private companies own 3.3%.

Nautilus Biotechnology's stock traded down 0.8% to $2.55, with 39,156 shares traded, a 47% decline from average volume. Analysts from Jefferies and Guggenheim initiated coverage with 'hold' and 'buy' ratings, respectively. The company reported a Q2 EPS of -$0.14, beating estimates by $0.02. Institutional investors like Axxcess Wealth and Price T Rowe increased their stakes in NAUT.